Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have been given an average recommendation of “Moderate Buy” by the ten brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $31.6667.

AVTX has been the subject of several research reports. TD Cowen assumed coverage on Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating for the company. BTIG Research reissued a “buy” rating and set a $40.00 price target on shares of Avalo Therapeutics in a research note on Monday, September 29th. HC Wainwright upped their price objective on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Cantor Fitzgerald initiated coverage on shares of Avalo Therapeutics in a report on Friday, August 15th. They set an “overweight” rating on the stock. Finally, Cowen assumed coverage on shares of Avalo Therapeutics in a research report on Friday, September 5th. They issued a “buy” rating on the stock.

Institutional Investors Weigh In On Avalo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BIT Capital GmbH purchased a new stake in Avalo Therapeutics during the 3rd quarter valued at about $25,000. Quadrature Capital Ltd purchased a new position in Avalo Therapeutics in the 2nd quarter worth approximately $55,000. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics in the second quarter valued at approximately $56,000. ADAR1 Capital Management LLC purchased a new stake in shares of Avalo Therapeutics during the first quarter valued at approximately $80,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Avalo Therapeutics during the third quarter valued at approximately $143,000. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Stock Up 5.8%

AVTX opened at $17.95 on Friday. The business’s fifty day simple moving average is $15.96 and its 200 day simple moving average is $10.15. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $19.41. The stock has a market cap of $325.43 million, a PE ratio of -3.35 and a beta of 0.84.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). As a group, equities analysts anticipate that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.